Skip to content
10-Q

Quarterly Report

IMMUNOVANT, INC. IMVT

0001764013-25-000129

← back to feed
Filed
Aug 11, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Aug 4, 2025 174.32M sh
Shares Diluted Q1 2026 · Jun 30, 2025 170.87M sh
Shares Diluted Q1 2026 · Jun 30, 2024 146.09M sh
Capex Q1 2026 · Jun 30, 2025 $0
Capex Q1 2026 · Jun 30, 2024 $182K
Operating Cash Flow Q1 2026 · Jun 30, 2025 −$117.41M
Operating Cash Flow Q1 2026 · Jun 30, 2024 −$76.2M
Cash And Equivalents Q1 2026 · Jun 30, 2025 $598.91M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $713.97M
Stockholders Equity Q1 2026 · Jun 30, 2025 $608.54M
Stockholders Equity Q1 2026 · Mar 31, 2025 $707.45M
Stockholders Equity Q1 2026 · Jun 30, 2024 $544.66M
Stockholders Equity Q1 2026 · Mar 31, 2024 $617.76M
Current Liabilities Q1 2026 · Jun 30, 2025 $52.9M
Current Liabilities Q1 2026 · Mar 31, 2025 $68.78M
Total Liabilities Q1 2026 · Jun 30, 2025 $52.9M
Total Liabilities Q1 2026 · Mar 31, 2025 $68.78M
Current Assets Q1 2026 · Jun 30, 2025 $651.76M
Current Assets Q1 2026 · Mar 31, 2025 $767.76M
Total Assets Q1 2026 · Jun 30, 2025 $661.44M
Total Assets Q1 2026 · Mar 31, 2025 $776.22M
Eps Diluted Q1 2026 · Jun 30, 2025 −$0.71
Eps Diluted Q1 2026 · Jun 30, 2024 −$0.60
Eps Basic Q1 2026 · Jun 30, 2025 −$0.71
Eps Basic Q1 2026 · Jun 30, 2024 −$0.60
Sga Expense Q1 2026 · Jun 30, 2025 $26.02M
Sga Expense Q1 2026 · Jun 30, 2024 $18.81M
Net Income Q1 2026 · Jun 30, 2025 −$120.61M
Net Income Q1 2026 · Jun 30, 2024 −$87.15M